Gennao Bio Inc is a biotech company based in Pennington, NJ, specializing in the development of targeted nucleic acid therapeutics. Their proprietary GMAB platform technology utilizes a unique cell-penetrating antibody to deliver nucleic acid payloads to specific cells, with a focus on oncology and rare monogenic skeletal muscle diseases.
With their adaptive and flexible GMAB technology, Gennao Bio can deliver various types of nucleic acids directly into the cell, targeting the nucleoside transporter ENT2 for better specificity and minimizing off-target effects. Their non-endosomal uptake mechanism enhances bioavailability of the payload, offering advantages over other antibody-targeted nucleic acid delivery systems. Led by an experienced executive team, Gennao Bio aims to transform genetic medicine by providing broad-based, systemic delivery, targeted cell transduction, dosing flexibility, and an improved safety profile.
Generated from the website